US Patent

US12138278 — Topical compositions

Formulation · Assigned to Bausch Health Ireland Ltd · Expires 2040-07-31 · 14y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a topical gel formulation containing clindamycin phosphate, benzoyl peroxide, and adapalene for treating inflammatory skin conditions like acne.

USPTO Abstract

The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same.

Drugs covered by this patent

Patent Metadata

Patent number
US12138278
Jurisdiction
US
Classification
Formulation
Expires
2040-07-31
Drug substance claim
No
Drug product claim
Yes
Assignee
Bausch Health Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.